BerandaCRSP • NASDAQ
add
Crispr Therapeutics AG
$37,78
Setelah Jam Perdagangan Normal:(0,00%)0,00
$37,78
Tutup: 16 Apr, 16.01.30 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$38,95
Rentang hari
$36,74 - $38,50
Rentang tahun
$30,06 - $67,88
Kapitalisasi pasar
3,24Â M USD
Volume Rata-Rata
2,16Â jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 35,69Â jt | -82,26% |
Biaya operasional | 18,12Â jt | 9,98% |
Laba bersih | -37,31Â jt | -141,76% |
Margin laba bersih | -104,54 | -335,40% |
Penghasilan per saham | -0,44 | -140,00% |
EBITDA | -59,75Â jt | -180,21% |
Tarif pajak efektif | -1,91% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 1,90Â M | 12,41% |
Total aset | 2,24Â M | 0,56% |
Total liabilitas | 309,95Â jt | -10,62% |
Total ekuitas | 1,93 M | — |
Saham yang beredar | 85,77 jt | — |
Harga terhadap nilai buku | 1,73 | — |
Tingkat pengembalian aset | -7,18% | — |
Tingkat pengembalian modal | -7,47% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -37,31Â jt | -141,76% |
Kas dari operasi | -50,03Â jt | 47,92% |
Kas dari investasi | 105,83Â jt | 229,93% |
Kas dari pembiayaan | 16,88Â jt | -56,66% |
Perubahan kas bersih | 72,59Â jt | 152,40% |
Arus kas bebas | -41,33Â jt | 68,36% |
Tentang
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Didirikan
2013
Kantor pusat
Situs
Karyawan
393
